<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01804920</url>
  </required_header>
  <id_info>
    <org_study_id>1600</org_study_id>
    <nct_id>NCT01804920</nct_id>
  </id_info>
  <brief_title>D-Serine Treatment For Tardive Dyskinesia</brief_title>
  <official_title>D-SERINE TREATMENT FOR TARDIVE DYSKINESIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herzog Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herzog Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Presently no generally effective treatments for tardive dyskinesia (TD) are available.&#xD;
      D-serine is a naturally occurring amino acid that acts in-vivo as positive allosteric&#xD;
      modulator at the glycine site associated with the glutamatergic NMDA receptor. Previous&#xD;
      studies have suggested that D-serine may improve motor symptoms, including dyskinesias, which&#xD;
      are caused by treatment with presently used antipsychotics drugs.&#xD;
&#xD;
      The hypothesis under investigation in the present study is that D-serine adjuvant treatment&#xD;
      may improve TD in schizophrenia patients diagnosed with this disorder.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in AIMS total score</measure>
    <time_frame>biweekly during a period of 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Schizophrenia and Schizoaffective Disorder</condition>
  <condition>Tardive Dyskinesia</condition>
  <arm_group>
    <arm_group_label>D-serine adjuvant treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Random assignment, parallel group, double blind, placebo controlled 8 weeks trial.&#xD;
First arm: D-serine adjuvant treatment, up to 4 g/day Second arm: Placebo adjuvant treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo adjuvant treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Random assignment, parallel group, double blind, placebo controlled 8 weeks trial.&#xD;
First arm: D-serine adjuvant treatment, up to 4 g/day Second arm: Placebo adjuvant treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D-serine</intervention_name>
    <arm_group_label>D-serine adjuvant treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo adjuvant treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age 18-70;&#xD;
&#xD;
          2. diagnosis of schizophrenia/schizoaffective disorder according to DSM-IV criteria;&#xD;
             diagnosis will be made on the basis of SCID interview and information from medical&#xD;
             records, previous treating psychiatrists, and family informants;&#xD;
&#xD;
          3. history of â‰¥3 months antipsychotic drugs treatment and present stable dose&#xD;
             antipsychotic treatment for at last 4 weeks;&#xD;
&#xD;
          4. fulfillment of Schooler-Kane TD research criteria on a first evaluation performed 2-12&#xD;
             weeks prior to study entrance and on a subsequent evaluation performed prior to&#xD;
             allocation to experimental treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. meeting criteria for other DSM-IV Axis I diagnoses;&#xD;
&#xD;
          2. presence of a neurological disorder or history of significant head injury;&#xD;
&#xD;
          3. substance abuse or alcoholism during entire lifetime;&#xD;
&#xD;
          4. are judged clinically to be at suicidal or homicidal risk;&#xD;
&#xD;
          5. female patients who are pregnant or lactating; female patients who are not pregnant or&#xD;
             lactating, if sexually active, must be using medically accepted means of&#xD;
             contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uriel Heresco-Levy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzog Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herzog Hospital</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>March 3, 2013</study_first_submitted>
  <study_first_submitted_qc>March 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2013</study_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herzog Hospital</investigator_affiliation>
    <investigator_full_name>Heresco-Levi Uriel</investigator_full_name>
    <investigator_title>Director - Psychiatry Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Tardive Dyskinesia</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

